Related Experiment Video

Updated: Dec 26, 2025

Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss
07:03

Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss

Published on: July 19, 2024

1.5K

Treatment of non-alcoholic fatty liver disease - Current perspectives

Anshuman Elhence1, Shalimar2

  • 1Department of Gastroenterology, All India Institute of Medical Sciences, Room No 127, 1st Floor, Human Nutrition Unit, New Delhi, 110 029, India.

Indian Journal of Gastroenterology : Official Journal of the Indian Society of Gastroenterology
|March 11, 2020
PubMed

Insights

Current non-alcoholic fatty liver disease (NAFLD) treatments focus on metabolic dysfunction, inflammation, and fibrosis. While no drugs are approved, therapies manage risk factors and comorbidities in high-risk patients.

Area of Science:

  • Hepatology
  • Metabolic Disorders
  • Pharmacology

Background:

  • Non-alcoholic fatty liver disease (NAFLD) progresses from metabolic derangement to inflammation, fibrosis, and cirrhosis.
  • Drug development for NAFLD has advanced, but no specific pharmacological agents are currently approved.
  • Treatment is prioritized for patients at high risk of progression, such as those with biopsy-proven steatohepatitis or fibrosis.

Purpose of the Study:

  • To provide a current perspective on therapeutic options for non-alcoholic fatty liver disease (NAFLD).

Main Methods:

  • Review of current therapeutic strategies and drug development in NAFLD.
  • Analysis of treatment approaches targeting pathogenic processes and risk factors.
  • Consideration of management for associated comorbidities.

Main Results:

  • No approved pharmacological agents currently exist for NAFLD management.
  • Therapeutic strategies target metabolic dysfunction, inflammation, and fibrosis.
  • Management includes addressing risk factors like dyslipidemia, insulin resistance, diabetes, and obesity.
  • Comorbidities such as cardiovascular disease, sleep apnea, and chronic kidney disease require concurrent management.

Conclusions:

  • Comprehensive management of NAFLD involves addressing the disease's progression, associated risk factors, and comorbidities.
  • Ongoing research and drug development aim to provide targeted therapies for NAFLD.
Keywords:
Body mass indexDyslipidemiaEpidemiologyMetabolic syndromeObesity

More Related Videos

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis08:58

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

Published on: March 11, 2017

16.7K
A Model of Experimental Steatosis In Vitro: Hepatocyte Cell Culture in Lipid Overload-Conditioned Medium08:35

A Model of Experimental Steatosis In Vitro: Hepatocyte Cell Culture in Lipid Overload-Conditioned Medium

Published on: May 18, 2021

7.3K

Related Concept Videos

Ultrasound II: Endoscopic Ultrasound and FibroScan01:25

Ultrasound II: Endoscopic Ultrasound and FibroScan

Endoscopic Ultrasound (EUS) and FibroScan are valuable diagnostic tools in gastroenterology and hepatology, each with specific applications and techniques.
Endoscopic Ultrasound (EUS):
432
Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
233
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
272
Overview of Fatty Acid Metabolism01:28

Overview of Fatty Acid Metabolism

Lipids also are sources of energy that power cellular processes. Like carbohydrates, lipids are composed of carbon, hydrogen, and oxygen, but these atoms are arranged differently. Most lipids are nonpolar and hydrophobic. Major types include fats and oils, waxes, phospholipids, and steroids.
Fatty acids are catabolized in a process called beta-oxidation, which takes place in the matrix of the mitochondria and converts their fatty acid chains into two-carbon units of acetyl groups. The acetyl...
35.9K
Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
1.7K
Chronic Pancreatitis I: Introduction01:24

Chronic Pancreatitis I: Introduction

The pancreas, an elongated and flat gland situated behind the stomach, serves a vital function in digesting food and managing blood sugar levels.
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...
616